DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

The aim of this paper is to outline pharmacotherapy of the ‘third-line management of CML’ (progressive disease course after sequential TKI drugs. Current management of CML with multi-TKI failure is reviewed. TKI (bosutinib, ponatinib, dasatinib, nilotinib) and non-TKI (omacetaxine mepussecinate, IFN...

Full description

Saved in:
Bibliographic Details
Main Author: Ibrahim C. Haznedaroglu
Format: Article
Language:English
Published: PAGEPress Publications 2015-02-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Online Access:http://www.mjhid.org/index.php/mjhid/article/view/2066
Tags: Add Tag
No Tags, Be the first to tag this record!